Dr. Eugene Dula

Dr. Eugene Dula
Eugene Dula, MD, FACS, is a board-certified urologist at San Fernando Valley Urological Associates. He provides comprehensive urological care to patients in West Hills and Tarzana, California. Dr. Dula was raised in Los Angeles and pursued his education close to home, graduating with a bachelor’s degree and honors from the University of California, Los Angeles. He received his medical degree from Mount Sinai School of Medicine in New York and returned to Los Angeles to do his Surgical and Urology training at Kaiser Foundation Hospital, which he completed in 1990. Dr. Dula has been in clinical practice in the San Fernando Valley since 1990 and is very active in the medical community. He served as the past Chairman of the Department of Urology and member of the Medical Executive Committee at Valley Presbyterian Hospital. He currently serves on the Ethical Review Board at Tarzana Hospital. Dr. Dula is a member of various urologic societies, including the American Urologic Association, and is a Fellow of the American College of Surgeons. As the medical director at West Coast Clinical Research, Dr. Dula has contributed to the advancement of new and emerging therapies in urology. He has been the Principal Investigator of over 200 clinical trials for the treatment of urologic conditions. Many of the most common medications for conditions such as ED, BPH, incontinence, and prostate cancer were initially studied in Dr. Dula’s facility. He serves as a medical consultant to the pharmaceutical industry, has authored multiple contributions to urologic literature, and has presented numerous papers to the urologic community, both nationally and abroad.
Medical School:

Mount Sinai School of Medicine


Kaiser Foundation Hospital

All surgical treatments have inherent and associated side effects. Individual’s outcomes may depend on a number of factors, including but not limited to patient characteristics, disease characteristics and/or surgeon experience. The most common side effects are mild and transient and may include mild pain or difficulty when urinating, discomfort in the pelvis, blood in the urine, inability to empty the bladder or a frequent and/or urgent need to urinate, and bladder or urinary tract infection. Other risks include ejaculatory dysfunction and a low risk of injury to the urethra or rectum where the devices gain access to the body for treatment. Further, there may be other risks as in other urological surgery, such as anesthesia risk or the risk of infection, including the potential transmission of blood borne pathogens. For more information about potential side effects and risks associated with Aquablation therapy for Benign Prostatic Hyperplasia (BPH) treatment, speak with your urologist or surgeon. Prior to using our products, please review the Instructions for Use, Operator’s Manual or User Manual, as applicable, and any accompanying documentation for a complete listing of indications, contraindications, warnings, precautions and potential adverse events. No claim is made that the AquaBeam Robotic System will cure any medical condition, or entirely eliminate the diseased entity. Repeated treatment or alternative therapies may sometimes be required.

Rx Only